Sunshine Biopharma, Inc. (SBFM)

NASDAQ: SBFM · Real-Time Price · USD
1.350
-0.040 (-2.88%)
Apr 30, 2025, 4:00 PM EDT - Market closed
Market Cap 4.91M
Revenue (ttm) 34.87M
Net Income (ttm) -5.13M
Shares Out 3.64M
EPS (ttm) -7.32
PE Ratio n/a
Forward PE 1.82
Dividend n/a
Ex-Dividend Date n/a
Volume 109,397
Open 1.350
Previous Close 1.390
Day's Range 1.310 - 1.350
52-Week Range 1.169 - 23.200
Beta 0.38
Analysts Strong Buy
Price Target 15.00 (+1,011.11%)
Earnings Date May 19, 2025

About SBFM

Sunshine Biopharma, Inc. operates as a pharmaceutical company that focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates through Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products segments. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; Adva-27a, a small chemotherapy molecule to treat pancreatic cancer; and K1.1 mRNA, a lipid nano-parti... [Read more]

Sector Healthcare
Founded 2006
Employees 52
Stock Exchange NASDAQ
Ticker Symbol SBFM
Full Company Profile

Financial Performance

In 2024, Sunshine Biopharma's revenue was $34.87 million, an increase of 44.75% compared to the previous year's $24.09 million. Losses were -$5.13 million, 13.9% more than in 2023.

Financial Statements

Analyst Forecast

According to one analyst, the rating for SBFM stock is "Strong Buy" and the 12-month stock price forecast is $15.0.

Price Target
$15.0
(1,011.11% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Sunshine Biopharma Launches Everolimus In Canada, an Oncology Drug with an Estimated Global Market of $2.5 Billion

FORT LAUDERDALE, FL / ACCESS Newswire / April 21, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic area...

9 days ago - Accesswire

Sunshine Biopharma Inc. Announces Closing of $2.46 Million Registered Direct Offering

FORT LAUDERDALE, FL / ACCESS Newswire / April 3, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of t...

27 days ago - Accesswire

Sunshine Biopharma Inc. Announces $2.46 Million Registered Direct Offering Priced at the Market Under Nasdaq Rules

FORT LAUDERDALE, FL / ACCESS Newswire / April 2, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of t...

4 weeks ago - Accesswire

Sunshine Biopharma Stock Shoots Higher On Encouraging Data From mRNA-Based Liver Cancer Drug

Sunshine Biopharma Inc. SBFM traded higher on Wednesday, with a session volume of 19.07 million compared to an average volume of 88.16K, according to data from Benzinga Pro.

4 weeks ago - Benzinga

Sunshine Biopharma Announces Positive Results of mRNA Therapy for Cancer

FORT LAUDERDALE, FL / ACCESS Newswire / April 2, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM) ("We", "Our", the "Company"), a pharmaceutical company offering and researching life-saving medicines in a...

4 weeks ago - Accesswire

Sunshine Biopharma Reports Revenue of $34.9M in Fiscal 2024, Up 45% From Last Year

FORT LAUDERDALE, FL / ACCESS Newswire / April 1, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of t...

4 weeks ago - Accesswire

Sunshine Biopharma Expands Presence in the $53.9 Billion Global Antibiotics Market with the Acquisition of Marketing Rights for Two New Antibiotics in Canada

FORT LAUDERDALE, FL / ACCESS Newswire / March 24, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic area...

5 weeks ago - Accesswire

Sunshine Biopharma Acquires Rights to Launch Two Gastrointestinal Drugs in the Canadian $200 Million Market

FORT LAUDERDALE, FL / ACCESS Newswire / March 10, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic area...

7 weeks ago - Accesswire

Sunshine Biopharma Expands Its Product Line to 69 Generic Prescription Drugs by Launching Olanzapine and Olanzapine ODT

FORT LAUDERDALE, FL / ACCESS Newswire / January 21, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety o...

3 months ago - Accesswire

Sunshine Biopharma Announces the Appointment of New Chief Commercial Officer

Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals is pl...

3 months ago - Accesswire

Sunshine Biopharma Announces Novel Inhibitor for Sars Coronavirus

FORT LAUDERDALE, FL / ACCESSWIRE / December 9, 2024 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of the...

5 months ago - Accesswire

Sunshine Biopharma Launches a New Generic Prescription Drug

FORT LAUDERDALE, FL / ACCESSWIRE / December 4, 2024 / Sunshine Biopharma Inc. (NASDAQ:"SBFM") (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of t...

5 months ago - Accesswire

Sunshine Biopharma Announces Breakthrough Research Results on the Company's K1.1 mRNA Product as a Novel Therapeutic Agent for Human Hepatocellular Carcinoma

FORT LAUDERDALE, FL / ACCESSWIRE / December 2, 2024 / Sunshine Biopharma Inc. (NASDAQ:"SBFM") (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of t...

5 months ago - Accesswire

Sunshine Biopharma Reports 2024 Third Quarter Results: Year-To-Date Revenues Up 54%

FORT LAUDERDALE, FL / ACCESSWIRE / November 6, 2024 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of the...

6 months ago - Accesswire

Sunshine Biopharma Launches Two New Generic Prescription Drugs

FORT LAUDERDALE, FL / ACCESSWIRE / September 26, 2024 / Sunshine Biopharma, Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of ...

7 months ago - Accesswire

Sunshine Biopharma Announces Publication of Significant Coronavirus Research Results in the Journal of Medicinal Chemistry

Current Test Positivity Rate for Coronavirus Infection in the U.S. is 18% Development of a novel antiviral compound, XR8-23 (Compound 10), targeting SARS-CoV-2 papain-like protease (PLpro) with both s...

8 months ago - Accesswire

Sunshine Biopharma Has Launched Nine New Generic Prescription Drugs in 2024: Now Marketing Sixty-One Generic Drugs in Canada

FORT LAUDERDALE, FL / ACCESSWIRE / August 26, 2024 / Sunshine Biopharma, Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of the...

8 months ago - Accesswire

Sunshine Biopharma Reports 2024 Second Quarter Results: Second QTR Revenues up 67%, YTD Revenues up 61%

FORT LAUDERDALE, FL / ACCESSWIRE / August 19, 2024 / Sunshine Biopharma, Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of the...

9 months ago - Accesswire

Sunshine Biopharma Announces Reverse Stock Split

FORT LAUDERDALE, FL / ACCESSWIRE / August 6, 2024 / Sunshine Biopharma, Inc. (NASDAQ:SBFM) (the "Company" or "Sunshine Biopharma"), a pharmaceutical company offering and researching life-saving medici...

9 months ago - Accesswire

Sunshine Biopharma's Nora Pharma Receives Health Canada Approval for Niopeg(R), a Biosimilar of Neulasta(R)

NEW YORK, NY / ACCESSWIRE / April 19, 2024 / Sunshine Biopharma Inc. (NASDAQ:SBFM), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including ...

1 year ago - Accesswire

Sunshine Biopharma Reports Operating Results for the Fiscal Year Ended December 31, 2023

Sales Grew at an Average Rate of 14% Per Quarter During the Year NEW YORK, NY / ACCESSWIRE / April 1, 2024 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering an...

1 year ago - Accesswire

Sunshine Biopharma, Inc. Announces Closing of $10.0 Million Underwritten Public Offering

NEW YORK, NY / ACCESSWIRE / February 15, 2024 / Sunshine Biopharma, Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeu...

1 year ago - Accesswire

Sunshine Biopharma, Inc. Announces Pricing of $10.0 Million Underwritten Public Offering

NEW YORK, NY / ACCESSWIRE / February 13, 2024 / Sunshine Biopharma, Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeu...

1 year ago - Accesswire

Sunshine Biopharma Moves Principal Office to New York City

NEW YORK, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Sunshine Biopharma, Inc. (NASDAQ: “SBFM”) (the “Company”), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeut...

1 year ago - GlobeNewsWire

Sunshine Biopharma Reports 2023 Third Quarter Results: Revenues up Significantly Over Last Year Due to a Key Acquisition

MONTREAL, QC / ACCESSWIRE / November 13, 2023 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeut...

1 year ago - Accesswire